Growth hormone activates renin-aldosterone system in children with idiopathic short stature and in a pseudohypoaldosteronism patient with a mutation in epithelial sodium channel alpha subunit.
Growth hormone (GH) treatment causes salt and water retention, and this effect has been suggested to be mediated by activation of epithelial sodium channel (ENaC). Multi-system pseudohypoaldosteronism (PHA) is a salt wasting disease resulting from mutations in ENaC subunit genes. We examined effects of GH therapy for 12-21 months on the renin-angiotensin-aldosterone system (RAAS) in 12 children with idiopathic short stature (ISS) and a PHA patient with defective ENaC function and concomitant GH deficiency. On GH therapy (0.7 U/kg/week), plasma renin activity (PRA), serum aldosterone and insulin-like growth factor-I (IGF-I) levels were periodically determined every 1-3 months in all children. The PHA patient was studied for 6 yr during which time serum, urine, and sweat electrolytes and secretion rate were also examined before, on and off GH therapy. In the PHA patient, mean plasma aldosterone concentration, 7.7 nmol/l (278 ng/dl) before therapy (n=9) rose to 73 nmol/l (2650 ng/dl) 10 months after GH. PRA and IGF-I increased similarly, reaching a plateau between 8 and 12 months. Off GH, there was a decrease to pretreatment levels in 30 months. Aldosterone and PRA strongly correlated with IGF-I (r=0.66 and 0.67). GH therapy also improved the growth rate, and increased both sweat secretion rate and Na(+)/K(+) ratio. In children with ISS, aldosterone and IGF-I peaked 6-12 months after GH. Off GH their levels normalized in 3 months. These findings indicate that long-term GH activates the RAAS in both children with ISS and a PHA patient, and that this effect does not depend on a fully functional ENaC.
Hanukoglu
A
A
Department of Pediatrics, E. Wolfson Medical Center, Holon 58100, Israel. aaronh@science.co.il
Belutserkovsky
O
O
Phillip
M
M
D000450:Aldosterone / Q000097:blood*; D001835:Body Weight; D002648:Child; D002658:Developmental Disabilities / Q000188:drug therapy / Q000378:metabolism*; D053503:Epithelial Sodium Channels; D013006:Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D009154:Mutation; D011546:Pseudohypoaldosteronism / Q000378:metabolism*; D012083:Renin / Q000097:blood*; D015222:Sodium Channels / Q000235:genetics*
D053503:Epithelial Sodium Channels; D015222:Sodium Channels; D000450:Aldosterone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D012083:Renin